MLEC

Malectin · Q14165 · MLEC on Sugi Atlas →

0 patent compounds predicted against MLEC, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MLEC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine PHASE4UNKNOWN
Hepatitis B Vaccination in Infants PHASE4COMPLETED
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Immunogenicity of the Booster Dose of Two MenC Vaccines PHASE4COMPLETED
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age PHASE4COMPLETED
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life PHASE4COMPLETED
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults PHASE3COMPLETED
Conjugate Vaccine Against Meningococcus C a Brazilian Project PHASE2/PHASE3UNKNOWN
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations PHASE3COMPLETED
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers PHASE3COMPLETED
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers PHASE2COMPLETED
Phase 1 Study of dmLT ID Vaccination in Healthy Adults PHASE1COMPLETED
Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea PHASE1COMPLETED
Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea PHASE1COMPLETED
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine PHASE1COMPLETED
MenPF-1 - A New Vaccine Against Meningococcal Disease PHASE1COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A nanCOMPLETED
Micro and Macro Circulation in Sepsis nanCOMPLETED
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease nanCOMPLETED
Neuro-Immune Interactions in the Gut nanCOMPLETED
Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery. nanUNKNOWN
Monocentric Retrospective Observational Study for Validation of Meta-analysis of the Metatrascryptome and Transcriptome of Eosynophyl Esophagitis nanUNKNOWN
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1 nanUNKNOWN
Placebo Controlled Study for Characterisation of Immunological Effects and Safety of Active O2 nanCOMPLETED
In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm nanCOMPLETED
An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease nanRECRUITING
PRIME Follow up - Quadri Meningo Vacinees nanCOMPLETED
Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis nanCOMPLETED
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MLEC binder may also engage these)

ProteinNameSimilarity
Q5FVQ4 1.000 Q5FVQ4 →
Q6ZQI3 0.998 Q6ZQI3 →
Q8AVF4 0.984 Q8AVF4 →
A9C3P0 0.984 A9C3P0 →
Q6INX3 0.982 Q6INX3 →
Q9UK99 0.963 Q9UK99 →
Q9DC63 0.962 Q9DC63 →
A6H7H7 0.962 A6H7H7 →
F1QR43 0.960 F1QR43 →
F1N9S8 0.959 F1N9S8 →
Q9MB58 0.958 Q9MB58 →
Q9EPS3 0.958 Q9EPS3 →
SSR1 Translocon-associated protein subunit alpha 0.957 landscape →
O94923 0.957 O94923 →
E9Q4Z2 0.956 E9Q4Z2 →
Q5R4X4 0.955 Q5R4X4 →
Q0J035 0.955 Q0J035 →
P16967 0.955 P16967 →
Q8C092 0.954 Q8C092 →
Q8CIF6 0.954 Q8CIF6 →
P79282 0.954 P79282 →
D4ABP9 0.953 D4ABP9 →
P49256 0.953 P49256 →
Q8IWV8 0.953 Q8IWV8 →
Q9CY50 0.953 Q9CY50 →
Q80YV4 0.953 Q80YV4 →
Q4R512 0.953 Q4R512 →
TAF5 Transcription initiation factor TFIID subunit 5 0.952 landscape →
Q6P4T2 0.952 Q6P4T2 →
O46606 0.952 O46606 →